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Abstract
Introduction and aim. Urothelial bladder carcinoma (UBC) is a very rare condition in patients aged below 50 years.
The aim of the study was to answer the question whether the characteristics of cancer in this group of patients differ from
general UBC features.
Material and methods. Altogether 2160 patients treated with primary transurethral resection due to a bladder tumor
were included in the study. The mean age of the cohort was 69.1 years (range 11–100). Patients were divided into three
subgroups depending on age: age <41 years (group 1), age 41–50 years (group 2), age >50 years (group 3). Sex ratio, tumor
grade, and stage of disease were recorded.
Results. Women constituted 18.5%, 19.2%, and 25.8% of the patients in groups 1, 2, and 3, respectively (P < 0.05).
WHO grade 3 tumors were diagnosed in 0%, 8.5%, and 17.2%, respectively (P < 0.05). Non-invasive papillary carcinoma was
found in 100.0%, 76.7%, and 62.7%, respectively (P < 0.05). The incidence of muscle-invasive bladder cancer was 0%, 11.0%,
and 15.6%, respectively (P < 0.05).
Conclusions. Pathological characteristics of UBC are dependent on the patients’ age. Being a very rare condition, UBC in
young patients is characterized by a relatively good prognosis.
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Introduction
Urothelial bladder carcinoma (UBC) belongs to the
most common urological malignancies. In a great
majority of cases, it affects patients in their sixth
or seventh decade of life. According to data from
the Polish National Cancer Registry, there were
5820 newly diagnosed bladder cancers in 2008 in
Poland. Among them only 48 (0.8%) were found
in patients aged below 40 years and 191 (3.3%) in
patients aged 40–49 years (1). On the other hand,
results of UBC treatment are still not satisfactory,
which has some particular importance in the con-
text of young patients. Despite the use of advan-
ced surgical techniques, intravesical and systemic
chemotherapy, intravesical immunotherapy as well
as radiotherapy, the 5-year overall survival in recent
large series of patients with muscle-invasive UBC
treated with radical cystectomy is reported to be as
low as 47% (2).
The impact of the age at onset on tumor biology
and prognosis of patients remains controversial.
H o w e v e r ,t h e r ei ss t i l la no p e nq u e s t i o na st o
whether tumor biology can determine the age of
cancer manifestation. While previous studies did
not answer deﬁnitively these important questions,
we investigated our database in order to deter-
mine the features of UBC in young patients and
to compare them with general bladder cancer
features.
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Material
Pathological records of 2160 consecutive patients
with newly diagnosed UBC in the period January
2000 to June 2011 were retrospectively analyzed.
The diagnosis was based on microscopic examination
of the specimen obtained during primary transure-
thral resection of the bladder tumor. Mean age of the
cohort was 69.1 years (range 11–100) (Figure 1).
Women constituted 25.2% (n = 545) of all patients.
Methods
Patients were divided into three subgroups depen-
ding on age: age <41 years (group 1, n = 27), age
41–50 years (group 2, n = 120),age >50 years (group 3,
n = 2013). For all groups we assessed male-to-female
ratio, tumor grade according to WHO 1973 classiﬁ-
cation, and stage of disease according to the TNM
2009 classiﬁcation.
Statistical analyses
Results are presented as numbers and percentages of
patients. The differences in qualitative variables were
compared with chi-square test using the Pearson
formula and considered to be statistically signiﬁcant
when the P value was < 0.05. Statistical tests were
performed for selected variables in the whole study
population deﬁned as three study groups and sepa-
rately for comparison between each study group.
When determining correlation, we used standard
correlation rate formula. All calculations were per-
formed with Statistica 9.0 software.
Results
Sex ratio
Male-to-female ratio was calculated to be 4.4 in
group 1, 4.2 in group 2, and 2.9 in group 3 (Figure 2).
The differences between study groups regarding sex
ratio were statistically signiﬁcant (P = 0.046). Detailed
statistical analysis showed low chi-square values and
P values > 0.05 when comparing group 1 to groups 2
and 3, which may depend on the fact that there were
just ﬁve women in group 1 (Table I).
Tumor grade
Detailed analysis regarding the number and percen-
tage of highly, moderately, and poorly differentiated
tumors in the different study groups showed that there
were substantial differences (P = 0.000) (Table II). We
also noticed a statistically signiﬁcant positive correla-
tionbetweenageandtumorgrade(r=0.126)(Figure3).
Stage of disease
Non-muscle-invasive UBC (Tis + Ta + T1) was found
in 27 patients (100%) in group 1, in 105 patients
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Figure 1. Age distribution within the study group.
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Figure 2. Sex distribution in the study groups.
48 S. Poletajew et al.(89.0%) in group 2, and in 1603 patients (84.4%) in
group 3 (Table III). These differences between the
study groups utilizing the TNM classiﬁcation system
were statistically signiﬁcant (P = 0.001). This also
meant that there was no muscle-invasive cancer amon-
gst the youngest patients, whereas 11.0% (group 2) and
15.6% (group 3) of the older patients suffered from
invasive (T2–T4) bladder carcinoma.
Discussion
We performed a pathology analysis of UBC features in
young patients and compared our results with features
of UBC in a typical population, which we deﬁned as
individuals of more than 50 years of age. To the best
of our knowledge, such an analysis has never been
done before based on consecutive and contemporary
patients, enrolling in total such signiﬁcant numbers of
patients younger than 50 years.
We found that the incidence of UBC in women
increased with age. In patients aged <41 years the
incidence was 4.5 times higher in men than in
women. It was only three times higher in patients
aged >50 years. In a previous investigation Shi et al.
showed that there was a male-to-female ratio of
4.1 in patients aged <41 years and 2.3 in patients
aged >60 years (3). Aboutaieb et al. showed that in a
group of UBC patients aged <40 years there were
men and women in proportions of 88.5% and
11.5%, respectively (4). However, when analyzing
the paper published by Migaldi et al, the male dom-
inance in young patients was not that clear. They
noticed that women constituted 32% of patients aged
<45 years and 12% amongst elderly patients (5).
Some general differences between Migaldi’sa n d
our ﬁndings may be due to the fact that they analyzed
only non-muscle-invasive UBC cases, while we
included all newly diagnosed UBC patients. Alanee
and Shukla analyzed data from the Surveillance,
Epidemiology and End Results (SEER) database
maintained by the American National Cancer Insti-
tute in the context of bladder malignancies among
children, showing a male-to-female ratio of 2:1.
However, UBC constituted only 51% of cancers in
the database. Thus, it is hard to determine the real
value of this report in the context of identifying UBC
features in young patients (6).
After analyzing the tumor grade in different age
groups, we conclude unambiguously that age corre-
lates with risk of presence of poorly differentiated
tumors. Also the paper published by Lerena et al,
which is an analysis of UBC in six children, presents a
100% incidence of low-grade carcinomas (7). Madrid
Garcia et al. found that six out of eight UBC patients
aged <40 years had G1 tumors (8). Fine et al. noticed
the presence of low-grade tumors in 8 of 11 (73%)
patients younger than 20 years (9). Low grade is
one of the most important factors, underlined by
Migaldi et al. and Cho et al, contributing to a better
prognosis of ‘young’ patients compared to ‘elderly’
patients (5,10).
Finally, we were looking for differences in stage
of the disease according to age. Our study showed
as i g n i ﬁcantly higher rate of muscle-invasive UBC
among patients aged >50 years compared to younger
patients. After calculating the incidence of muscle-
invasive UBC in patients aged <50 years, it turned
out that it was almost half that of older patients. The
results of a majority of previously published papers
are comparable to ours (7–9,11–13). However, there
are publications showing opposite results. The study
by Ozbey et al. presents a 36% incidence of muscle-
Table I. Comparison of analyzed parameters between different age groups.
Group 1 versus 2 Group 1 versus 3 Group 2 versus 3
Parameter/Group Chi- square P value Chi- square P value Chi-square P value
Sex ratio 0.54 0.82 0.75 0.39 5.03 0.02
Grade 20.92 0.00 36.96 0.00 7.28 0.05
Stage 11.25 0.02 14.64 0.01 11.49 0.02
Table II. Number and percentage of highly (G1), moderately (G2), and poorly (G3) differentiated tumors.
Parameter/Group Group 1 Group 2 Group 3 P value
Grade (1973 WHO) G1 21 (77.8%) 36 (30.5%) 510 (26.0%) 0.000
G2 6 (22.2%) 72 (61.0%) 1113 (56.8%)
G3 0 (0%) 10 (8.5%) 336 (17.2%)
Bladder carcinoma in young patients 49invasive UBC in 25 patients aged <40 years (14), while
the correspondingvalue inthe study ofAboutaieb etal.
was extremely high and amounted to 58% (4). Both
studies cited above were conducted in the 1990s,
and the only argument for such a difference in results
may be the observation of an increasing number of
clinically silent and incidentally diagnosed cancers.
An additional value of our report is the statistics on
the stage of UBC at the time of diagnosis in Poland.
Such a report has not been published previously.
While announced for the ﬁrst time in Poland, its
data are similar to those presented by other European
investigators (15).
We used the 1973 WHO classiﬁcation, which is
still helpful in grading, despite the presence of more
recent WHO and International Society of Urological
Pathology (ISUP) classiﬁcations. This phenomenon
is not unique, since many European pathologists
(over 42%) still use the primary WHO classiﬁcation
due to its clear criteria and simplicity (16). It is also
worth remembering that the clinical superiority of
newer classiﬁcations compared to the 1973 WHO
classiﬁcation has not been conﬁrmed (17–19).
The most important limitation of our study is the
relatively small number of patients in study group 1.
Even though we analyzed a 10-year-period with
over 2100 cases of newly diagnosed UBC, we recru-
ited only 27 cases of patients aged 40 or less and
147 patients aged 50 or less. Because of the changing
biology of neoplasms over the past years, we believe it
would not be scientiﬁcally justiﬁed to analyze longer
periods of time. The solution of the problem might be
a national UBC registry including pathological and
clinical data, which we, however, at present lack.
Another important limitation of our study is its
retrospective character. We did not re-evaluate
microscopic slides, and our analysis is based exclu-
sively on archival medical documentation. We are
conscious of the fact that microscopic assessment
of specimens obtained during transurethral resec-
tion of bladder tumors belongs to the most challen-
ging in histopathology, with relatively high staging
and grading errors, as well as a relatively high
inter- and intra-observer variability (20–25). How-
ever, 95.2% of the slides included in our study were
evaluated by the same, experienced uropathologist.
A third limitation of our study might be the fact
that we have not performed any clinical analysis in
terms of follow-up studies. Such data would play an
important role in the characterization of the biology
of UBC in young patients.
Based on the results of our study, we conclude that
characteristics of urothelial bladder cancer differ
depending on the patients’ age. In young patients,
compared to patients aged more than 50 years, can-
cer occurs more frequently in men, more frequently
as low-grade tumors, and the disease at the time of
diagnosis is more frequently at a low stage, not
requiring radical cystectomy. Bladder cancer is a
very rare condition in young patients; however, if
it occurs, it is characterized by a relatively good
prognosis.
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